Metformin and vascular protection: A diabetologist's view

Diabetes and Metabolism

Volumn 29, Issue 4 II, 2003, Pages

  Garber, A J ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Cardiovascular risk factors; Glycaemic control; Metabolic syndrome; Type 2 diabetes

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE CONTROL; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; TREATMENT PLANNING; VASCULAR DISEASE; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; RISK ASSESSMENT;

EID: 0642311108     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(03)72795-5     Document Type: Review

References (20)

1. American Diabetes Association. Diabetic nephropathy. Diabetes Care, 2002, 25 (suppl. 1), S85-89.
2. nd edition, Ed Harris MI. Bethesda, MD: National Institutes of Health and national Institute of Diabetes and Digestive and Kidney Diseases, 349-85.
3. American Diabetes Association. Diabetic retinopathy. Diabetes Care, 2002, 25 (suppl. 1), S90-939.
4. Expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 2002, 25 (suppl. 1.), S5-20.
5. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-53.
6. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med. 1993, 329,977-86.
7. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care, 2002, 25 (suppl. 1), S25-7.
8. American Diabetes Association. Implications of the UK Prospective Diabetes Study. Diabetes Care 2002, 25 (suppl. 1), S28-32.
9. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 1993, 16, 434-44.
10. Wei M, Gaskill SP, Haffner S, Stern MP. Effects of diabetes and levels of glycaemia on all-cause and cardiovascular mortality. Diabetes Care, 1998, 21, 1167-72.
11. nd edition. Bethesda, MD: National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases, 1995, 233-55.
12. Laakso M. Hyperglycaemia and cardiovascular disease in type 2 diabetes. Diabetes, 1999, 48, 937-42.
13. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J, 2000, 321, 405-12.
14. UK Prospective Diabetes Study Group. Effect ofintensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352, 854-65.
15. Bailey CJ. Antidiabetic drugs. Br J Cardiol, 2000 7, 350-60.
16. Wiernsperger NF, Metformin: intrinsic vasculoprotective properties. Diabetes Technol Ther, 2000, 2, 259-72.
17. Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications, 2002, 16, 401-15.
18. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic-agents. Drug Saf, 1994, 11, 223-41.
19. Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br J Diabetes Vasc Dis, 2001, 1, 28-36.
20. Howlett HC, Bailey CJ, A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf, 1999, 20, 489-503.